Dyne Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Dyne Therapeutics, Inc. (DYN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $11.10 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-07-29
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $10.71, a 39.27% increase year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $7.69, a 52.12% decline year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $16.06, a 95.38% increase year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $8.22, a 42.96% increase year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $7.24, a 62.33% decline from fiscal 2024.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $19.22, a 164.01% increase from fiscal 2023.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $7.28, a 16.67% increase from fiscal 2022.
- Dyne Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $6.24, a 39.00% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $11.10 10-Q · filed 2026-07-29 | ||||
| 2026-03-31 | $10.71 10-Q · filed 2026-05-11 | ||||
| 2025-12-31 | $7.24 10-K · filed 2026-03-02 | ||||
| 2025-09-30 | $6.78 10-Q · filed 2025-11-05 | ||||
| 2025-06-30 | $6.85 10-Q · filed 2026-07-29 | ||||
| 2025-03-31 | $7.69 10-Q · filed 2026-05-11 | ||||
| 2024-12-31 | $19.22 10-K · filed 2026-03-02 | ||||
| 2024-09-30 | $9.65 10-Q · filed 2025-11-05 | $19.65 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $17.04 10-Q · filed 2025-07-28 | ||||
| 2024-03-31 | $16.06 10-Q · filed 2025-05-08 | ||||
| 2023-12-31 | $7.28 10-K · filed 2026-03-02 | ||||
| 2023-09-30 | $7.79 10-Q · filed 2024-11-12 | ||||
| 2023-06-30 | $7.93 10-Q · filed 2024-08-12 | ||||
| 2023-03-31 | $8.22 10-Q · filed 2024-05-02 | ||||
| 2022-12-31 | $6.24 10-K · filed 2024-03-05 | ||||
| 2022-09-30 | $5.33 10-Q · filed 2023-10-30 | ||||
| 2022-06-30 | $4.54 10-Q · filed 2023-08-03 | ||||
| 2022-03-31 | $5.75 10-Q · filed 2023-05-11 | ||||
| 2021-12-31 | $10.23 10-K · filed 2023-03-02 | ||||
| 2021-09-30 | $11.68 10-Q · filed 2022-11-03 | ||||
| 2021-06-30 | $11.78 10-Q · filed 2022-08-04 | ||||
| 2021-03-31 | $11.44 10-Q · filed 2022-05-02 | ||||
| 2020-12-31 | $4.50 10-K · filed 2022-03-10 | ||||
| 2020-09-30 | $4.27 10-Q · filed 2021-11-04 | ||||
| 2020-06-30 | $0.71 10-Q · filed 2021-08-05 | ||||
| 2020-03-31 | $0.68 10-Q · filed 2021-05-06 | ||||
| 2019-12-31 | $0.62 10-K · filed 2021-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |